Pestell’s StromaGenesis Highlights AI’s Expanding Role in Cancer Care
The latest venture from Dr. Richard Pestell, StromaGenesis, combines biotech entrepreneurship with AI-powered cancer detection. The Wynnewood company has raised $175,000 toward a $10 million Series A financing target while developing three diagnostic tests for multiple cancer types. Its StromaAI engine is built to analyze complex biological and pathology data, supporting prostate cancer risk assessment, companion diagnostics, and solid tumor therapy response prediction. Pestell’s history as a cancer center leader, professor, and company founder gives the project added credibility. As StromaGenesis seeks funding, it highlights the expanding connection between artificial intelligence and precision cancer diagnostics in today’s precision medicine landscape.

Comments
Post a Comment